Myocarditis induced by a novel bifunctional PD-1/CTLA-4 combination antibody: a case report and literature review
{{output}}
Background: Combined PD-1/CTLA-4 blockade improves overall survival in advanced cancers but increases the risk of severe myocarditis. Iparomlimab and Tuvonralimab (Qibian®), a novel bifunctional anti-PD-1/CTLA-4 antibody, has re... ...
